Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib
A 70-year-old man with metastatic renal cell carcinoma developed progressive liver metastases after 8 weeks of treatment with the multitargeted tyrosine kinase inhibitor (TKI) sunitinib. He then participated in the phase III placebo-controlled clinical trial of the oral mammalian target of rapamycin...
| Main Authors: | , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Springer US
2010
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3219862/ |